235 related articles for article (PubMed ID: 22029000)
1. Pioglitazone: Indian perspective.
Shukla R; Kalra S
Indian J Endocrinol Metab; 2011 Oct; 15(4):294-7. PubMed ID: 22029000
[TBL] [Abstract][Full Text] [Related]
2. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
Olansky L; Marchetti A; Lau H
Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.
Chilcott J; Tappenden P; Jones ML; Wight JP
Clin Ther; 2001 Nov; 23(11):1792-823; discussion 1791. PubMed ID: 11768834
[TBL] [Abstract][Full Text] [Related]
4. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
5. Effects of replacing metformin with pioglitazone on glycemic control in japanese patients with poorly controlled type 2 diabetes mellitus: A 12-week, open-label, prospective study.
Sakaue S; Kamigaki M; Yoshimura H; Nishimura M
Curr Ther Res Clin Exp; 2008 Aug; 69(4):364-77. PubMed ID: 24692813
[TBL] [Abstract][Full Text] [Related]
6. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone: beyond glucose control.
de Pablos-Velasco P
Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1057-67. PubMed ID: 20670183
[TBL] [Abstract][Full Text] [Related]
8. Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide.
Schwartz S
Curr Med Res Opin; 2008 Nov; 24(11):3009-22. PubMed ID: 18828960
[TBL] [Abstract][Full Text] [Related]
9. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
10. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Eur J Pharmacol; 2009 Jan; 602(2-3):448-54. PubMed ID: 19038243
[TBL] [Abstract][Full Text] [Related]
11. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis.
Abe M; Okada K; Maruyama T; Maruyama N; Soma M; Matsumoto K
Expert Opin Pharmacother; 2010 Jul; 11(10):1611-20. PubMed ID: 20540652
[TBL] [Abstract][Full Text] [Related]
13. Hybrid drug combination: Anti-diabetic treatment of type 2 diabetic Wistar rats with combination of ellagic acid and pioglitazone.
Nankar RP; Doble M
Phytomedicine; 2017 Dec; 37():4-9. PubMed ID: 29103827
[TBL] [Abstract][Full Text] [Related]
14. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
15. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
[TBL] [Abstract][Full Text] [Related]
16. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
Musholt PB; Schöndorf T; Pfützner A; Hohberg C; Kleine I; Fuchs W; Hehenwarter S; Dikta G; Kerschgens B; Forst T
J Diabetes Sci Technol; 2009 Nov; 3(6):1442-50. PubMed ID: 20144400
[TBL] [Abstract][Full Text] [Related]
17. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
[TBL] [Abstract][Full Text] [Related]
18. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.
Martens FM; Visseren FL; de Koning EJ; Rabelink TJ
J Cardiovasc Pharmacol; 2005 Dec; 46(6):773-8. PubMed ID: 16306801
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
Neeser K; Lübben G; Siebert U; Schramm W
Pharmacoeconomics; 2004; 22(5):321-41. PubMed ID: 15061682
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on pioglitazone in type 2 diabetes mellitus.
Waugh J; Keating GM; Plosker GL; Easthope S; Robinson DM
Treat Endocrinol; 2006; 5(3):189-91. PubMed ID: 16677060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
